Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
17 août 2023 08h00 HE
|
Repligen Corporation
Bioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementationCustomers experience optimized facility equipment...
Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
02 août 2023 07h30 HE
|
Repligen Corporation
– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year – Adjusts full year revenue guidance to range of $635-$665...
Repligen to Report Second Quarter 2023 Financial Results
19 juil. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2023 financial results on Wednesday, August 2,...
Repligen Corporation to Present at Upcoming Investor Conferences
31 mai 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
02 mai 2023 07h30 HE
|
Repligen Corporation
Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currencyReports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP)...
Repligen to Report First Quarter 2023 Financial Results
18 avr. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2023 financial results on Tuesday, May 2, 2023....
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
14 mars 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
22 févr. 2023 07h30 HE
|
Repligen Corporation
Fourth quarter revenue of $186.8 million represents year-over-year organic growth of 4% and 5% growth at constant currencyFull year revenue of $801.5 million represents year-over-year organic growth...
Repligen Appoints Martin D. Madaus to Board of Directors
09 févr. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D....
Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
08 févr. 2023 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on...